This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk12: Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q1 2021 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct the question and answer session. If you wish to put yourself in the question queue, please press 1 and 0 at this time or when instructions are given. As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Mr. Kevin Hearn. Please go ahead.
spk10: Good morning. Thank you for joining us for Eli Lilly and Company's Q1 2021 earnings call. I'm Kevin Hearn, Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chairman and CEO, Anat Ashkenazi, Chief Financial Officer, Dan Skowronski, Chief Scientific Officer, Anne White, President of Lilly Oncology. Ilya Yufa, President of Lilly Biomedicines, Mike Mason, President of Lilly Diabetes, and we'd also like to welcome Jake Van Narden, CEO of Loxo Oncology at Lilly, who will be joining us today and moving forward to answer your questions about discovery and early-stage oncology efforts he's leading. Now, I'll turn the call over to Dave. Oh, sorry. We're also joined by Sarah Smith and Lauren Zierke of the Investor Relations Team. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on slide three. Additional information concerning factors that could cause actual results to differ materially is contained in our latest forms 10-K and subsequent forms 10-Q and 8-K filed with the Security and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, a reminder that our commentary will focus on non-GAAP financial measures. Now, I'll turn the call over to Dave for a summary of our results from the first quarter of 2021.
spk09: Okay, thanks, Kevin. Lilly Enterer 2021 focused on expanding our reach to over 45 million patients by scaling our key growth brands around the world. Continuing the advancement of our pipeline, following a very successful 2020, and increasing productivity in the SG&A line while investing in research for sustainable long-term growth. We are pleased with the progress we've made on these objectives in our first quarter, while also delivering hundreds of thousands of doses of our COVID-19 antibodies to patients to help the continued fight against COVID-19. As we unpack this quarter's results, we will attempt to give you a clear picture of the underlying trends in our core business. We recognize this quarter was noisy, catching the increased consumer stock in from the Q1 2020 in our quarterly compare and increased COVID-19 therapy R&D spend in 2021. These items coupled with the FX rate movement and a number of changes to U.S. government purchase agreements for COVID-19 antibodies throughout the quarter make for a longer earnings call and press release, and we realize for those keeping score on sell-side model accuracy, perhaps some disappointment. Nonetheless, underneath all that is a strong and growing core business for Lilly and a significant number of positive, even compelling, pipeline readouts in the quarter to support long-term growth across all of our core therapy areas. And we continue to expect top-line growth and margin expansion to accelerate throughout this year. This quarter, revenue grew 16% compared to Q1 2020, or 13% in constant currency. This performance was driven entirely by volume, which grew 17 percentage points. As previously highlighted in Q1 2020, we had roughly a $250 million COVID-19 related inventory build that is impacting the year-over-year comparison. When excluding COVID-19 antibody revenue, and the Q1 2020 stocking benefit, our core business grew 7% for the quarter. Key growth products continued to drive volume and revenue growth and now represent 52% of our core business in Q1 2021. Our non-GAAP gross margin was 75.4% in Q1 and 78% excluding the impact of foreign exchange on international inventories sold. Our non-GAAP operating margin was 27.5% for the quarter and 30.1% excluding the FX impact. While foreign exchange on international inventories sold has a modest effect on our results in 2019 and 2020, in the first quarter of 2021, we experienced over a 250 basis point of negative impact on our gross margin and operating margin. Recall that is purely a non-cash accounting item. On the pipeline front, we achieved multiple milestones since our Q4 earnings call, including the Phase III initiation of pertabrutinib, formerly known as LOXO-305, and for additional obesity studies in terzipatide's Surmount program. The FDA granted emergency use authorization for the administration of bamlanivimab and edesivimab together as a treatment for COVID-19. positive Phase III results from terzipatide-surpassed 2, 3, and 5 trials in type 2 diabetes, and positive Phase III results for murikizumab in ulcerative colitis and baricitinib in alopecia areata. About a decade ago, Lilly made the decision to enter into and invest in immunology with the Phase III initiation of ixikizumab, now known as TALTS. Since then, we have added Illumient in rheumatoid arthritis, and several new indications with first or best in category data for TALTS and Illumiant in rheumatology and dermatology. This year, we see further expansion of our immunology strategy with the successful completion of Phase III studies of mirakizumab in ulcerative colitis, the first IL-23 P19 antibody medicine to demonstrate results in this setting. We're also excited about Leberkizumab's potential to differentiate from Dupixent on itch, sleep, and safety, primarily in conjunctivitis, in what is an increasingly large and growing class with meaningful unmet medical need. And we anticipate multiple Phase III readouts for Leberkizumab later this year in monotherapy and in combination with corticosteroids. We look forward to potentially reaching increasing numbers of patients in difficult-to-treat immunology conditions in the coming years. We also entered into several business development deals, including the in-licensing of a RIPK1 inhibitor from Rigel Pharmaceuticals and the divestiture of Cubregza, which, along with leberkizumab, was part of the Dermura acquisition last year. We also distributed nearly $800 million in dividends this quarter, with the dividend per share increasing 15% versus last year. Moving on to slides five and six, you'll see a list of key events since our last earnings call. We announced plans to host a webinar to provide an overview of the company's commitment in the areas of environmental, social, and governance for the investment community, for media, and the general public on May 4, 2021. Additionally, we announced two planned retirements of long-tenured executives and several additions to our leadership team. I'd like to thank Miles O'Neill, President of Lilly Manufacturing, and Melissa Barnes, our Chief Ethics and Compliance Officer, for their leadership and service to our company. We also extend a warm welcome to Edgardo Hernandez, who will be succeeding Miles, to Alonzo Weems, who will succeed Melissa, and to Diogo Rao, who will be joining Lilly next month as Chief Information and Digital Officer for succeeding Artie Shaw, whose retirement was announced last fall. Finally, we announced the appointment of Anat Eskenazi, our CFO. Anat has a deep experience having been the CFO of every part of our value chain. For the last four years, Anat has led a large portion of our finance organization with all of our divisional CFOs reporting to her, as well as our accounting and financial reporting team, our corporate strategy group, and our business transformation office. During this time, Anat worked closely with me, our executive committee, and our board of directors to develop and implement our annual business and long-term strategic plans. I have no doubt that Anat will perform extremely well as CFO of Lilly and expect no changes in our priorities, our strategy, or execution, given her significant involvement in all those areas. Anat, welcome to our leadership team, and I'll turn the call over to you for our Q1 results.
spk18: Thanks, Dave. Slide 7 summarizes our non-GAAP financial performance in the first quarter. As Dave mentioned, revenue increased 16% this quarter compared to Q1 of 2020, or 7% when excluding the COVID-19 antibody revenue and the Q1 2020 COVID-related stocking benefit, representing a good momentum for our core business. Last year, with the health and safety of our employees, patients, and providers in mind, we shifted from in-person interactions to primarily virtual interactions and began 2021 with few sales reps in the field in the U.S. We feel good about our capabilities to work with providers virtually and are encouraged as we exited Q1 2021 with a majority of U.S. reps back in the field. As we navigate the early stages of the recovery, we're focused on operational excellence in both virtual and in personal environments and are pleased with the volume and shared growth in key brands despite continued pandemic-related headwinds for several classes. As we look at gross margin, gross margin as a percent of revenue declined 490 basis points to 75.4%. Excluding the impact of foreign exchange on international inventory sold, gross margin as a percent of revenue was 78%, a decrease of 260 basis points, primarily due to the unfavorable product mix driven largely by sales of COVID-19 antibodies and to a lesser extent by lower realized prices and revenue. Moving down the P&L, operating expenses grew 11% compared to the same quarter last year. Marketing, selling, and administrative expenses increased 2%, while R&D expenses increased 21%, driven primarily by $220 million of investments in COVID-19 therapies. Net of the COVID-19 expenses, R&D increased 5%, driven by continuing investments in our late-stage pipeline. Total operating expense growth was less than 3% compared to Q1 2020 when excluding the investments in COVID-19 therapies. Operating income increased 6% compared to Q1 of 2020, and operating income as a percent of revenue was 27.5% for the quarter, a decline of 250 basis points compared to prior year. This decline was driven entirely by the impact of foreign exchange on international inventory sold. Other income and expense was income of $35 million this quarter compared to expense of $73 million in Q1 of 2020, driven primarily by a benefit related to favorable European patent settlement for Olympia. As we noted previously, beginning in 2021, we are excluding the gains or losses due to equity investments from our non-GAAP measures and have provided revised figures for 2020 in our investor workbook to enable year-over-year comparison on that same basis. Our effective tax rate was 10.8%, a decrease of 210 basis points compared with the same quarter last year. The effective tax rate for both periods was reduced by net discrete tax benefit with a larger net discrete benefit reflected in the first quarter of 2021. At the bottom line, net income and earnings per share increased 16%. On slide 8, we quantify the effect of price, rate, and volume on revenue growth across the world. U.S. revenue grew 18% compared to the first quarter of 2020, while revenue decreased slightly, excluding COVID-19 antibodies. Adjusting for the Q1 2020 stocking benefit, the core business grew 5% in the U.S. These results were driven entirely by volume, laid by trelicity and talk, partially offset by a mid-single-digit price decline. Pricing was a 6% drag on U.S. revenue growth this quarter, driven primarily by TOLTS' improved access and corresponding higher contracted rates partially offset by a modest list price increase. Excluding the impact of TOLTS' win at ESI, we experienced low single-digit net price decline in the U.S. in the first quarter of 2021. We noted on previous calls that we expected TOLTS would experience price headwind in Q1 beyond general rate pressure with the improved access position. there were two pieces of the ESI impact. The first, existing patients already covered through medical exceptions were moved to the newly contracted rate, a one-time step down in prices as we move through 2021. In addition, we were pleased with the update for new patients at ESI at the contracted rate, and we expect that that population will grow meaningfully over time. There is always a near-term impact when we have a significant step up in access and this win nearly doubled our commercial access. We're encouraged by the volume growth we saw in the first quarter and believe TALS will return to net sales growth in the second quarter, which should continue to accelerate as we move through the year, as the volume growth from the major access upgrade outpaces the related price and headwinds. Beyond TALS, segment MEC was not a major of U.S. price performance in the first quarter, as increased utilization in the more highly rebated government segments was offset by lower utilization in the 340B segment, primarily for a diabetes portfolio. While mid-term trends are stable at present, given the increase in variability in peer mix, we continue to expect quarterly variability in reported net price changes. We also expect tulch price impact to moderate as we move through the year, and overall, low to mid-single digit total net price decline in the U.S. for the full year. Moving to Europe, revenue grew 15% in constant currency. Excluding COVID-19 antibody revenue and the impact of Q1 2020 COVID-related stocking, revenue grew 5% in constant currency, despite lockdowns in a number of European countries, and driven primarily entirely by volume growth for a limited . We're pleased with the momentum of our business in Europe and are looking forward to continued strong growth in 2021. In Japan, revenue decreased 8% in constant currency, driven entirely by decreased volume for Cialis and Forteo. Net of the impact for those post-patent expiry products, Japan grew 5% in constant currency, driven by Versenio, Jardines, in collaboration with BI, and Illumiant. In China, revenue grew 26% in constant currency, driven by 32% volume growth, primarily from Tyvet, and to a lesser extent, our diabetes portfolio. We're excited about the momentum in China as our business has accelerated significantly the past two quarters. Tyvek continues its strong growth. Trulicit and Illumiant are now in the NRDL, and we look forward to launch uptake for Verzenio. Revenue in the rest of the world decreased 1% in constant currency, driven primarily by continued erosion of Cialis. As shown on slide 9, our key growth products continue to drive impressive volume growth. Despite the Q1 2020 COVID-related stocking benefit impacting year-over-year growth, these newer medicines delivered over a 9 percentage point of growth this quarter, with COVID antibodies also contributing roughly 14 percentage points of growth. The strong volume growth was partially offset by post-LOE products as well as insulin, whose volume growth was also meaningfully impacted by the Q1 2020 stocking benefit. Slide 10 highlights the contribution of our key growth products In total, these brands generate approximately $3.1 billion in revenue this quarter and made up 52% of core business revenue. We are particularly encouraged by Trulicity's performance. Three years ago, Trulicity was the number two injectable glyphine in the U.S. market at roughly 40% share of market. Weekly scripts for the class were approximately 180,000, and a new weekly injectable entrance had just launched. Since that time, Trulicity has become the most prescribed GLP-1 in the U.S., with a 48% share of the injectable market in a class that is now twice the size at roughly 360,000 weekly scripts. Trulicity continues to have the highest adherence of any diabetes medication, oral or injectable, with the additional dose of 3 and 4.5 milligrams, providing the potential for Trulicity to both extend the time on therapy for existing patients and compete for new patients, as demonstrated by the new-to-brand share of market, having increased more than four points since the launch of these additional doses in September 2020. As we start 2021, we are pleased with Trulicity's ability to outgrow the injectable class and establish all-time highs in new therapy starts, as well as total market share. We see meaningful opportunity for continued robust class growth for GLP-1s as they are still less than 1 in 10 diabetes scripts and have significant opportunity for further penetration in the first injectable space as well. With more positive readouts from the truceptide and type 2 diabetes this quarter, we remain focused on sustaining trulicity leadership position, accelerating class growth, and providing continued innovation in the encrypting space. On slide 11, we provide an update on capital allocation. In Q1, we invested nearly $3 billion to drive our future growth through a combination of business development, capital expenditure, and after-tax investments in R&D. In addition, we returned nearly $800 million to shareholders via dividend. We are focused on utilizing our cash flow, our strong cash flow, to develop the next wave of new medicine through both internal and external sources, as highlighted by the recently completed in-licensing of the RIP Kinase 1 inhibitor for myelopharmaceuticals. We will remain active in assessing in-licensing opportunities as well as bolt-on acquisitions where we believe we can create shareholders' value and enhance our future growth prospects. Turning to our 2021 financial guidance on slide 12, we are updating our GAAP and non-GAAP guidance. We continue to support healthcare professionals navigating the ongoing pandemic and driving broad vaccinations to enable return to normalcy for healthcare systems in the second half of the year. Despite some therapeutic class still at or below pre-COVID baselines for new therapy starts and the highlighted inventory impact on year-over-year growth, we are confident in the performance of our core business. We are increasing our full-year revenue outlook by $100 million to reflect the FX benefit realized on the top line in the first quarter. We are, however, narrowing the range for COVID-19 antibody revenue. from approximately $1 to $2 billion to $1 to $1.5 billion for the year. Based on the rollout of the vaccine across major markets, current antibody utilization rate, existing U.S. government bemlanivimab supply, and the transition to only supply bemlanivimab and edesivimab administered together in the U.S. We believe this update range contemplates a variety of potential scenarios. We recognize that situations across the globe can evolve quickly and will plan to adapt as required moving forward. The net impact of these changes is an updated revenue range of $26.6 billion to $27.6 billion. Our outlook for gross margin percent remains unchanged with the impact of COVID-19 antibodies diluting our total gross margin percent by approximately 100 basis points. For research and development, we're increasing our range from 6.5 to 7.7 to 6.9 to 7.1 billion. This reflects an increase of 100 million in COVID-19 antibody expense to support the advancement of a third antibody, LY-1404, as we continue to address the COVID-19 pandemic. And approximately 300 million on the core business driven by investments in Denonimib for the expansion of the Phase III Trailblazer II study and the initiation of a new Phase III study, Trailblazer Alzheimer's III in asymptomatic Alzheimer's patients. Our investments in the Nanomab is consistent with our R&D strategy to continue to bolster our pipeline to ensure long-term growth and based on the strength of the data, invest meaningfully in innovative molecules that we believe have the potential to deliver practice-changing data that could significantly improve patient outcomes in areas of high unmet need. We're increasing our non-GAAP range for OID to an expense of $100 to $200 million to reflect the limited pedant settlement in Europe I noted earlier, while our GAAP range is now income of $150 to $250 million, which reflects the impact of equity investment gains in the first quarter. We are lowering our effective tax rate to approximately 13% to reflect higher discrete tax items in the first quarter and the lower base rates. We're lowering our non-GAAP operating margin guidance to approximately 31%. The decrease in operating margin is driven entirely by the decreased investments in Alzheimer's for the Nanomeb. Our longer-term margin expansion remains unchanged as we expect continued operating margin expansion to mid to high 30s. Our gap operating margin is expected to be approximately 26%. Finally, the non-gap range for earnings per share is now $780 to $8. The increase on the lower end of the range reflects the net benefit for the core business related to the changes to OID and tax rate, as well as increased revenue, offset by increased R&D for investments in the Nanomab. The reduction in the upper end of the range reflects the narrow revenue range and increased R&D expense for COVID-19 therapies. Our GAAP EPS is expected to be in the range of 703 to 723, which reflects an increase to acquired IP R&D related to completed business development transactions, other specified items related primarily to asset impairment, COVID-19 inventory charges, and acquisitions integration costs, as well as the benefit from net gains on investments in equity securities. We're confident in our ability to achieve our 2021 revenue goals for the core business, while also delivering operating margin expansion and mid-teens EPS growth. As we move forward, I would encourage you to look at trends in our core business for the first half of the year, given the significant variability we saw across in 2020. As a reminder, revenue performance in the second quarter of 2020 was impacted by the reversal of largely all the $250 million COVID-related stocking benefit from Q1 of 2020, as well as an additional $250 million due to the significant decline in new patients' prescription as healthcare utilization decreased and systems temporarily closed down in the face of a surging pandemic. As we look at underlying volume and share trends across our key products, we are confident in our full-year outlook for the core business, And the pipeline successes in the first quarter only furthers our conviction and our mid-term and long-term outlook for continued revenue growth and operating margin expansion. Now I will turn the call over to Dan to highlight progress in R&D.
spk05: Thanks, Anat. 2021 is clearly off to a very positive start for R&D at Lilly, with strong pipeline progress already and more potential catalysts on the way. Before I get into the broader portfolio update, I'll spend a few minutes highlighting results from Terzepatide's first four top-line readouts from the Phase III SURPASS program, including the strong results from SURPASS II, the head-to-head trial with semaglutide 1 milligram. This program is aptly named, as we've seen Terzepatide surpass our expectations through these initial readouts. displaying significantly greater hemoglobin A1C reduction, weight loss, and percent of patients reaching normal glucose levels than any GLP-1 on the market. On slide 13, you can see impressive performance in the efficacy estimate analysis in glycemic control for Terzapetide, with each dose demonstrating superiority in each trial across a range of patient populations, comparators, and background medications. A clear highlight is the impressive A1C reduction of the 5-milligram dose across each of these different patient populations, while the higher doses provide additional glucose control up to and surpassing 2.5% A1C reductions. Moving to slide 14, you can see how Terzapatide performed across all three doses in terms of patients achieving HbA1c below 5.7%. a normal glycemic level seen in people without type 2 diabetes. We believe this is an exciting finding that may reset expectations for the impact diabetes medications could have for patients. Using the efficacy estimate analysis across Surpass 1, 2, and 3, we see about half of the patients on the 15-milligram dose of terzapatide achieved this remarkable level of HbA1c control. In Surpass 5, which focused on patients on background insulin glargine, 62% of patients on 15 mg Terzepatide achieved this level of A1c, compared to only 3% of patients in the placebo group. Remember, this is a patient population on background basal insulin with an average duration of diabetes of over 13 years. Achieving this level of glucose control in such a population is something that prior to GIP GLP-1 agonists like Terzepatide, we did not even contemplate as possible. On slide 15, we show the efficacy estimate analysis for weight reduction across the four studies. Here again, we see levels of efficacy that previously were thought unobtainable with incretin therapy in type 2 diabetes patients. As we and others have discussed, studies like AWARD-11 and SUSTAIN-FORTE have begun to show the limit of what fully hitting the GLP-1 mechanism can accomplish for weight loss in A1C. There appear to be diminishing returns as doses of GLP-1 alone fully saturate the GLP-1 receptor-mediated mechanism, and a flattening of the dose-response curve occurs. And then you look at this slide, including, importantly, SURPASS-2, and you can see quite clearly that there's something different going on here, as the dual GIP-GLP-1 receptor agonist is beyond the flattening of the dose-response curve of GLP-1 performance, which we believe evidences the power of adding in the GIP mechanisms. Highlights from these studies include the 15-milligram dose, delivering 14% weight reduction in SURPASS-3, noting here weight gain of 3% on insulin degladec comparator, the 15-milligram dose nearly doubling the weight reduction of semaglutide 1 milligram in SURPASS-2, and strong performance from the 5 and 10-milligram doses with statistically superior weight loss, even as high as 11% on the 10-milligram dose, versus placebo or active comparators. We're encouraged that in these 40- and 52-week studies, we haven't yet seen the weight loss curves plateau on the higher doses. It's really exciting to think about how terzapatide could potentially perform with the longer duration of treatment that we'll see in future studies. We had a lot of confidence in the efficacy data coming out of Phase II, but there was a lot we didn't yet know about safety and tolerability. Recall, for example, that the primary phase 2 trial had only about 200 patients on therapy, and patients were only on therapy for 26 weeks. As we look at slide 16, we've been pleased to see through these four surpassed readouts that the overall safety profile was similar to the well-established GLP-1 receptor agonist class, and the most commonly reported adverse events were GI-related and mild to moderate in severity. We're particularly encouraged by the potential impact of the optimized dose escalation scheme, and accordingly by the tolerability profile observed in the phase three program, which improved greatly in comparison to phase two, including the lower rates of nausea, diarrhea, and vomiting that we've seen, consistent with what we saw in phase three studies for other well-tolerated and highly used incretin therapies, including our own Trulicity. In addition, we're pleased with the discontinuation rates due to adverse events, which have ranged from three to 11% across doses in these studies. Stepping back from the data bit, We're excited about the safety and efficacy results across all doses, but perhaps especially so for the efficacy of the 5-milligram dose, which is performed well in each study, including showing superiority to semaglutide 1 milligram and surpassed 2 on both A1C reduction and weight loss. I think these data show that the 5-milligram dose could be a great first incretin that can potentially deliver best-in-class efficacy with tolerability that is as good or better than other leading incretins. So we have the low maintenance dose of 5 milligrams that, if approved, could potentially be appropriate for many patients, with physicians knowing they could have higher doses available as they continue management of disease. Terzapatide could provide patients with the opportunity to set treatment goals that might surpass what was previously thought possible in type 2 diabetes, both in terms of getting patients to normal glucose control, which has never been contemplated as a potential treatment goal, as well as for impressive weight loss. with the highest dose of Terzepatide having roughly double the weight loss of some of Glutide 1 milligram. It surpassed 2. Today, type 2 diabetes is largely a treat-to-fail disease. With these results, Terzepatide, if approved, could potentially provide doctors options to enable early control of glucose and weight. This has the potential to translate to improved levels of end-organ protection and a more meaningful reduction in disease complications than has yet been seen. We'll be testing this potential for triseptide in ongoing and planned studies in diabetes, obesity, heart failure, and NASH. Accordingly, we've now initiated Surmount 2, 3, and 4 for triseptide and obesity, and top-line results from Surmount 1 are expected next year. Moving back to diabetes, the top-line readout for Surpass 4, which is in a high cardiovascular risk population and we believe will provide an important contribution to our CV safety assessment, is the gating trial for global submissions in type 2 diabetes. Completion of this trial has always been contingent on accruing a pre-specified number of CV events. We've achieved the necessary events, which triggers bringing patients in for final treatment and safety visits before moving the trial to completion. Based on this update, we anticipate a top-line readout by the middle of this year. We look forward to disclosing the results of SURPASS 1, 2, 3, and 5 at the ADA 2021 virtual meeting, which will include a 90-minute ADA symposium featuring these results the morning of June 29th. While we're excited with the progress of Terzepatide, we think innovation in the incretin space is not over. At ADA, we'll also be discussing preclinical and phase 1 data for our glucagon GLP-GIP triagonist, also known as GGG. which we're pleased to announce will be moving into phase two later this quarter. We've previously commented that in this space, we have a high bar for progressing molecules in development, one that has been raised recently by Terzapatide. While it's still early, we're advancing Triple G to phase two based on our belief that it could exceed the benefits seen with Terzapatide. With our Triple G molecule, we expect to see even more weight loss than what can be achieved with Terzapatide while preserving glucose-lowering efficacy. In addition, due to glucagon's direct action on the liver, we'd also hope to see benefits in NASH. Consequently, our ambitious Phase II program is designed to evaluate GGG for obesity, type 2 diabetes, and NASH. In addition to our next-generation incretins, we're also very excited by our novel weekly insulin, Basal Insulin FC. Thanks to Lily's work on trulicity, weekly incretin therapy is now the standard of care in the GLP-1 space. And together with Terzapatide, we hope incretin-based therapies will become the standard of care in the first injectable space for people with type 2 diabetes. For those people who need basal insulin therapy in addition to their incretin therapy, we'd like to make weekly insulin therapy possible, ultimately avoiding daily injections completely. We'll give an update at ADA on our novel weekly basal insulin. We plan to have an investor call on the morning of July 1st to discuss the data releases at ADA for Trizepatide, Triple G, and weekly basal insulin. While the progress in our diabetes portfolio is compelling, Lilly has continued to advance the rest of our pipeline this quarter. Slide 17 shows select pipeline opportunities as of April 23rd, and slide 18 shows potential key events for the year. In addition to the progress on Trizepatide I just discussed, major developments since our last earnings call include progress with Denenumab on multiple fronts. In terms of data, we presented detailed results at ADPD showing Denenumab met its primary endpoint, significantly slowing cognitive decline compared to placebo on the integrated Alzheimer's disease rating scale, a composite measure of cognition and daily function in patients with early symptomatic Alzheimer's disease. And data from secondary analyses showed Denenumab consistently slowed cognitive and functional decline with ranges between 20% and 40% in all secondary endpoint. with nominal statistical significance at multiple time points compared to placebo. On the clinical front, as we discussed in detail on our call last month, we expanded Trailblazer ALS II to be a Phase III study, and it's now enrolling quickly. And today, we're announcing that we will start a new Phase III study, Trailblazer ALS III, in asymptomatic Alzheimer's disease. This trial is anticipated to begin enrollment later this year. Our goal here is to enroll patients who already have Alzheimer's brain pathology but don't yet have any clinical symptoms. The study will have development and progression of Alzheimer's disease symptoms as the primary endpoint, and we anticipate it will take approximately three years from completion of enrollment to reach a sufficient number of events. We'll be testing if a short course of Denenumab treatment at the start of the trial can prevent progression in a substantial fraction of patients over the subsequent several years. These types of trials are extremely challenging to enroll and conduct, but here we're buoyed by our expertise in biomarkers, including both PET scans and, importantly, our plasma pTAL217 assay. On the regulatory front, based on feedback from the FDA, we currently do not see a path forward for near-term submission and approval based on the first Trailblazer OWL study alone. As you know, the unmet need in Alzheimer's disease is significant, So while we remain focused on speeding up enrollment and completion of our second pivotal study, Trailblazer ALS II, we are continuing to actively engage with the FDA and are fully exploring any opportunities for early submission. Another highlight this quarter was the initiation of pertubrutinib's Phase III program, with study start in chronic lymphocytic leukemia as monotherapy. We're also proud of the continuation of our work against COVID-19 including a planned transition from bamlanivimab alone to the administration of bamlanivimab and etesevimab together for the treatment of COVID-19 in the U.S., accomplished by first gaining emergency use authorization for bamlanivimab and etesevimab administered together in February, and then our request for revocation of the EUA for bamlanivimab alone, which FDA subsequently granted. We also submitted bamlanivimab and etesevimab administered together for regulatory review in Europe, and we initiated the evaluation of Bamlanivimab with Vir7831 in collaboration with Vir and GSK, as well as started trials with a new, potentially broadly neutralizing antibody, LY1404, in collaboration with Abcelera, in case new combinations are needed to fight variants. We announced top-line Phase III results, evaluating baricitinib on top of standard of care, which did not meet statistical significance on the primary endpoint for treatment of COVID-19, but did result in a significant reduction of death from any cause by 38% by day 28. And baricitinib received regulatory approval in conjunction with remdesivir as a treatment for COVID-19 in Japan. Our work on terzepatide, deninamab, and pirtobrutinib brings great potential for patients in the long term and is highly prioritized at Lilly. Our work on COVID-19 is another clear highlight where we moved quickly to help address an unmet medical need in the midst of a pandemic. We're optimistic, though, that this need will wane in the coming years. Beyond these significant efforts, there's been progress across many other commercial stage and clinical stage assets. Starting in oncology, we're pleased with the approval of selpercatinib for non-small cell lung cancer and thyroid cancer in Europe. We're also pleased that the results of MONARCH-E, our adjuvant breast cancer study, are now submitted in Japan, along with Europe, China, and the U.S., As you know, the primary endpoint for the study was invasive disease-free survival, which we hit at the interim analysis. As anticipated, this hazard ratio continues to strengthen over time as more events have accrued. Important secondary endpoints for the study include distant relapse-free survival and overall survival. For the U.S. submission, the FDA has noted, and we agree, that the OS data are immature and thus unreliable, as we shared in the JCO publication last year. FDA has therefore asked us to see an updated OS analysis during the review cycle to determine that OS is trending in favor of Resenio. Given the robust distant relapse-free survival data, we're highly confident that the overall survival data will eventually reflect and reinforce the survival benefit. But it takes time for these events to accrue, especially in the adjuvant setting. In immunology, we have positive phase III readouts for baricitinib in alopecia areata, a disease with significant unmet medical need. and we look forward to regulatory submissions starting in the second half of this year. We also announced that the FDA extended the review period for baricitinib for atopic dermatitis by three months, another disease where we think JAK inhibition could potentially alleviate important unmet medical needs. With mirakizumab, we reported positive Phase III results in ulcerative colitis in the 12-week induction study, hitting the primary endpoint and all key secondary endpoints, and we look forward to seeing the maintenance data early next year. We also have updates to the Mirakizumab psoriasis program. While the OASIS program generated positive results with safety and efficacy similar to other IL-23 P19s, we believe the psoriasis market is well served with highly effective treatment options, including TELTS. Lilly's immunology strategy is to focus our new molecules and indications on areas where patients have significant unmet needs, not merely adding new options or leveraging commercial presence to create a space where effective solutions like TALTS already exist for patients. Therefore, we will not pursue submission of merikizumab and psoriasis, but instead we'll focus our efforts on the ulcerative colitis and Crohn's disease indications where unmet medical need is higher and where we believe the potential of the IL-23 P19 mechanism to create a new standard of care is greater. In addition to late-stage progress, our early-stage portfolio continues to advance. with the introduction of five new Phase I assets and the attrition of two. In addition to the progress we've made in just the first few months of the year, we anticipate important developments for the remainder of 2021, including the final readout for Gizepatide's Phase III Type II diabetes program, Surpass IV, noted earlier, Phase III results for Jardians in HEF-PEF, and for Leberkizumab in atopic dermatitis. Regulatory actions for Jardiance for Hef-Ref, Verzenio in the adjuvant setting for ER-positive breast cancer, Baricitinib for atopic dermatitis, and Tenezumab for osteoarthritis pain, where we previously noted our disappointment in the outcome of the Tenezumab Advisory Committee. The presentation of Phase I data for our oral SIRD, the initiation of Phase I for a BCL-2 inhibitor and for a KRAS-G12C inhibitor, along with the filing of an IND for a next-generation RET inhibitor later this year, as we announced at AACR, and the Phase II readout for Zagotenimab, our anti-Tau antibody for early Alzheimer's disease. We believe our continued pipeline success drives increasing visibility to meaningful long-term growth. We look forward to continued progress across our portfolio in the coming quarters. Now I turn the call back over to Dave for some closing remarks.
spk09: Thanks, Dan. Before we go to Q&A, let me briefly sum up the progress we've made to start the year. Amid several moving pieces in a challenging healthcare environment, we are excited by the momentum we are seeing. Our business grew 16% in the first quarter, with the core business growing 7%, adjusted for COVID-19 antibody revenue and last year's COVID-19 related inventory stocking benefit. Our top line growth continues to be strong, driven strongly by volume across our key growth products, which account for more than half of our core business. Net of the significant impact from foreign exchange on international inventories sold, our operating margin was in line with our expectations as we continue to expect operating margin expansion throughout the year and further expansion in years to come. We made significant progress developing new medicines, with many more data readouts expected this year. Advances for Terzipatide, Dononimab, Pertabrutinib, Brisenio, Mirakizumab, Ritefmo, and Illumiant serve as a reminder of the breadth and depth of opportunities we have to sustain robust long-term growth. We return nearly $800 million to shareholders, being an increased dividend, reflecting confidence in the ongoing strength of our business. I want to say thank you to my Lilly teammates, whose commitment to excellence and dedication to our purpose of bringing innovative new medicines to patients is inspiring and drove these accomplishments amidst ongoing pandemic headwinds. While our people, healthcare providers, and patients continue to face near-term challenges associated with COVID-19, our long-term outlook is as bright as ever. This concludes our prepared remarks, and now I'll turn the call over to Kevin to moderate the Q&A session.
spk10: Thanks, Dave. We'd like to take questions from as many callers as possible, so we ask that you limit your questions to two per caller. Tawny, can you please provide the instructions for the Q&A session, and then we're ready for the first caller.
spk12: Thank you. Ladies and gentlemen, if you wish to ask a question, please press 1, then 0 on your telephone keypad. You may withdraw your question at any time by repeating the 1-0 command. Our first question comes from the line of Chris Schott with J.P. Morgan. Please go ahead.
spk22: Great. Thanks so much, and appreciate all the color on today's call. I'm just going to do two on the pipeline. I guess first on Virginio, did I hear that you mentioned FDA is looking for updated LS data as part of the review? So I was just wondering when you'll have that data And does that push out approval timelines in a meaningful way that we need to think about? And then the second one I had was on triseptide. I guess just in light of the data you've seen from the SURPASS studies, has that changed how you think about what patient populations you'll focus on from a commercial standpoint or your go-to-market strategy? And I guess as part of that, as we think about triseptide coming to market, do you expect substantial switches from trulicity? Or is triseptide growth more about new patient starts and kind of expanding the market? Thanks so much.
spk10: Thanks, Chris. We'll go to Ann for the Resenio question, and then Mike on terseptide.
spk20: Well, thanks, Chris, for the question on Resenio. And so we will be delivering this data set to the FDA without delaying our standard review timing. We can't really comment on what the FDA will do with the data or the application, but these discussions are progressing as planned. Important to note, as the data matures, I think as Dan said, Given the strength of the DRFS hazard ratio, remember it was a 0.687 hazard ratio with a very strong p-value, we are highly confident that the OS will trend in favor of Resenio. So really what we believe we're discussing is when that will occur. So obviously, as I said, we can't comment on the discussions at FDA, but we do look forward to working with them on bringing this medicine to patients. And maybe just a comment to reference how immature this data is. At the time of the interim analysis that we published in JCO late last year, there were 39 deaths in the Abema arm and 37 in the control arm. So that makes it really challenging to interpret this data when there's over 5,000 patients in the study. Thanks for the question.
spk14: Thanks, Ann. Mike? Chris, thanks for your question. No, the drosepatite results have not changed the way we want to position drosepatite in the marketplace. We're obviously very pleased with those results. We're also just really blessed to have both Trulicity and Tersepitide, and our goal will be to maximize our entire Incotrend portfolio. Trulicity has established a strong market position, and I think the best data to support that is just how we've been able to grow share of market in the face of Asympic and Rebelsis. So it has a strong position in the marketplace, and that will remain. But now, as we think about Tersepitide, the dual Incotrend mechanism, that GIP component, is really a game-changer for us. You know, Dan went through the results, but we just haven't seen the ability to return someone living with type 2 diabetes, whether they're late or early, someone with type 2 diabetes progression, back to normally when seen. In fact, we were able to get 50% to 60% of people back. It's really incredible. Also, weight loss at the highest dose up to 14%. So when you just take a look at that and you take a look at the fact that 90% of people who live with type 2 diabetes are overweight or obese, they can really benefit from early treatment with type 2 diabetes. So the real question is, why would you want to put them on something else early on, and why would you want to wait for them to have those benefits? So we see trisepatide has the potential to really transform the market, drive an earlier use of incretins, in particular trisepatide's dual mechanism, and really expand the incretin market. So, you know, I think trisepatide will clearly win some new patients that would have went on to Trulisti. You'll have some people who were or maybe not performing well or are needed more efficacy that will go on to trisepatide. But clearly our focus will be to profoundly change and disrupt the type 2 diabetes marketplace by driving earlier use of icrotrans with trisepatide. Thanks, Mike.
spk10: Chris, thanks for your questions. Next caller, please.
spk12: Yes, our next question comes from the line of Jeff Meacham with Bank of America. Please go ahead.
spk15: Morning, guys. Thanks for taking the question. I also have two pipeline ones. I just wanted to get your perspective on Merakizumab, the decision to focus on just IBD. You know, you have good head-to-head data in psoriasis, so is it more of a commercial focus, or is it that you want to focus more on TALTS and psoriasis? And then in Alzheimer's, you'll have Zagatinumab data in the second half of this year. How are you thinking about the opportunity to combine potentially with donanumab? I wasn't sure what steps need to happen prior to, you know, thinking about that type of trial and maybe from a regulatory perspective, you know, what do you think would be a gain factor? Thank you.
spk10: Thanks, Jeff. We'll go to Ilya for the first question and then Dan for the question on Alzheimer's.
spk11: Great. Jeff, thank you for the question. On mirakizumab, really, as we see the greatest opportunity for unmet need for patients, and we've said all along, we believe that mirakizumab has the greatest opportunity in GI and IBD and ulcerative colitis and Crohn's disease. We were pleased with the Lucent One results, and so we're looking forward to seeing the maintenance data at the early part of next year. In terms of psoriasis, as we take a look at the market and unmet need, We do continue to believe that TALTS is the gold standard and best in disease, and I believe that really is a market well served. And so the decision from a portfolio standpoint is to focus our efforts in places where we believe we can have the greatest unmet need, and GI is where we're focused for Amerikizumab.
spk05: Thanks, Celia. Dan? Yeah. Thanks, Jeff, for the question on Zagatenumab, our anti-Tau antibody. Before I come to combinations, maybe I just handicap this Phase II trial quickly. The pro here in favor of Tau is clearly genetic validation and pathologic validation of the target. It's a great target for Alzheimer's disease. The cons here that we have to acknowledge is data from other companies' tau antibodies, which hasn't been particularly promising, and the difficulty in hitting the tau target in the brain. Now, we have a differentiated antibody here that binds just aggregated tau, so perhaps there's reason to think we could get different results. We're certainly eagerly awaiting those data in the second half of the year. And you're exactly right. If we see efficacy, combination would be an important consideration here. For sure, the general theme of combining an anti-amyloid drug with an anti-Tau drug is a good one, particularly when you have a drug like Denetimab where you can completely clear amyloid plaques with a limited duration of therapy. And then perhaps at that moment, intervene with an anti-Tau drug. I do think that's the future. It's something we're actively considering, pending, of course, data on the Tau antibody.
spk10: Thanks, Dan. Jeff, thanks for your questions. Next caller, please.
spk12: Thank you. Our next question comes from Vamil Devan with Mizuho Securities. Please go ahead.
spk16: Great. Thanks so much for taking the questions. Maybe one on Tau. Maybe just a little more clarity or color on the pricing dynamics there. You mentioned you're kind of expecting a return in net sales growth in the second quarter and then accelerating. I'm just trying to think about it as we think about the four-year dynamics. I know you don't give product level guidance, but how you think about sort of the kind of four-year comparison for 2021 to 2020. I assume you're still expecting growth for the year as a whole, but if you could just sort of clarify, is that contract with ESI, I'm not sure, is that a four-year contract or does that go beyond one year? I'm just trying to get a sense of sort of FOMI, pricing dynamics in 2022 and 2023, and we should expect another step down. And then one quick follow-up just on the comments around Trailblazer 3. I don't know if you can maybe just share a little more in terms of the number of patients you're looking to enroll in that trial, just so we can kind of get a sense of how long the enrollment might actually take. Thank you.
spk10: Thanks, FOMI. We'll go to Ilya for the question on TALTS and kind of the four-year picture, and then Dan on Trailblazer 3.
spk11: Sure. So on TALTS, first, let me just say we're really pleased about the progress we're making on TALTS and the growth that we're seeing with the step-up in access upgrades, ESI and beyond. And so as we take a look, even though that we've had some price impact in Q1, there are some elements there where we have a number of patients that were on medical exception that are now in the rebated contract that we have with ESI. Of course, we're also seeing an increase in overall volumes with ESI. What's encouraging is that we're not only seeing improvements in overall volume based off of switches, we're also seeing significant improvement in our new therapy starts. And so we're in dermatology now the leading share in dermatology with over 19% share, and then in rheumatology, we're almost doubling our share from previous year. And so as we think about the year in terms of growth, we do believe we'll get to net sales growth in Q2, and we'll continue to accelerate that volume growth throughout the year. The contracting that we have for TALTS goes beyond one year, and so we're encouraged about the volume growth of over 20% now, and we continue to see encouraging signs in the market.
spk05: Thanks, Ilya. Dan? Yeah, thanks very much for the question on Trailblazer 3 and our enrollment goals here. We probably don't get into too many details here, but we are, of course, expecting this to be a large trial involving thousands of individuals. But yet, we also set very ambitious enrollment goals. And while we don't have all the details planned out on how to achieve this, Our goal is that we should be able to enroll this trial in about a year. That's pretty exciting to contemplate. An Alzheimer's prevention trial is something that makes great sense given the science and the biology here and what we know about the onset of Alzheimer's disease and its relation to years of having amyloid plaque in the brain. But there have been two major drawbacks that have not made these trials really very practical. First is finding the patients. That has gone from impossible before our introduction of amyloid PET scan to possible but really hard with amyloid PET scans as we experienced firsthand in the A4 trial to now something that's eminently feasible. with our advent of the Phosphatau-217 assay. That's a huge advance that just unlocks this trial. The second is if you think about this population, which is not experiencing symptoms, is a bit younger than an Alzheimer's population, and introducing a therapy that is likely an infusion that they take for the rest of their lives, that's also a pretty significant hurdle. Again, we've, I think, abrogated that risk with Denenumab and a limited treatment duration to give lasting plaque clearance. So, excited about the Trailblazer 3 trial.
spk10: Thanks, Dan. Vamo, thanks for your questions. Next caller, please.
spk12: Thank you. Our next question comes from Samus Fernandez with Guggenheim. Please go ahead.
spk13: Great. Thanks so much for the question. Just first off, a question for Dave. You know, Dave, as you think about some of the various proposals that are in Congress currently, could you just give us your thoughts on, you know, the tax proposal? And maybe Anat could give a little bit of the potential implications for Lilly. And then separately, there's obviously a lot of controversy swirling on drug pricing. Just wanted to get your sense of the proposals that are out there currently and if the industry is poised to or ready to step up with a more reasonable proposal. And then just the second question is on the JAK inhibitor space and Lilly's opportunity with Leberkizumab, particularly in atopic dermatitis. There's a bit of a compare and contrast. Only Lilly, I think, has both potential opportunities in the space. I think there's a lot of speculation that there is going to be a safety update from the FDA, if not a full safety panel. Hoping, Dan, that you could give us a little bit of your thoughts in that regard. Thanks so much.
spk10: Thanks, Seamus. Lots to unpack there. We'll start with Dave on some of the policy, maybe a nod on the tax piece of that, and then we'll go to Ilya on kind of what he sees from a Jack and Leverkusen standpoint.
spk09: Yeah. Hi, Seamus. Look, on tax, this is a live discussion, of course, because the President's introduced a number of ideas on corporate tax changes. I guess we join a growing chorus of large companies who oppose That means to raise revenue, especially when the stated policy goal of the infrastructure plan is to build back the economy. Of course, private money and corporate actions make up the vast majority of the investment that could or would occur, and taxing that seems like a bad idea, maybe the opposite idea from the bill itself. Within the bill, maybe just a couple of general comments, and we can follow up if we need to. You know, there's the nominal rate discussion, which, of course, when we say moving from 21 to 28 is, you know, moving toward the middle of the pack, is not true because, of course, in the U.S. we have state-level income tax. It would really put the U.S. at the highest developed economy in terms of corporate tax rate. Additionally, we're the only major economy that taxes overseas earnings of its domiciled companies, and changing the so-called GILTI tax, foreign minimum tax, really is punitive to our home companies in multiple ways and is something that would have a disproportionate effect on pharmaceutical companies. And so both these actions don't make a lot of sense to us and we oppose. We would favor things like looking at funding the IRS so they can collect taxes from all the people that don't pay, including businesses and other items that can be paid for. We certainly support infrastructure in many ways. On drug pricing, you know, this has been pushed out a little bit. I wouldn't be surprised if we see H.R. 3 being debated soon, but as you may have read, apparently it won't be part of the second package from the White House. That's good because H.R. 3 and those concepts are really set to take a huge piece out of the industry, do nothing for patient out-of-pocket affordability, and really derail the innovation machine that is the only reason we're escaping from the COVID-19 pandemic. So we will oppose that with every ounce of our being at pharma. That said, we are all for changes to the system that make out-of-pocket costs go down for patients. There are a lot of ways to do this within the system that the industry is willing to put pay force on the table. This is much more around the contours of maybe what we saw with Senate Finance or the reported proposals made in the 11th hour of the last administration. We will table those ideas. We are tabling those ideas. And I think probably in the second half you'll hear more about that. We think there's a great opportunity to improve affordability. and strengthen the healthcare system and really address healthcare inequities as well that occur because people who are of lower economic means, people of color, women are disproportionately affected by bad insurance design and bad benefit design. We can shore those up and make the healthcare system work better for everyone. Thanks, Dave.
spk11: Ilya? Yeah, Seamus, so thank you for the question. As you noted, you know, and what we said on the call is that we're quite excited about our progress in immunology as a whole. And if we think about the growth opportunities within immunology, topic dermatitis is one catalyst for the company, both in what we believe in Illumion's success, but also Leprakizumab. In terms of the question around Jackson FDA decision, I won't speculate on any decision the FDA may make, But it's safe to say that the delay across all JAKs in atopic dermatitis and other indications suggest that there's a broader review on JAK safety. We feel that Illumiant has a robust safety profile, and with dermatology being more safety conscious, we do believe that Illumiant has a very good prospect to compete in this space, especially after a topical failure. And then labrakizumab is one to watch out for for the second half of the year as we get more data, where we feel like we can compete and differentiate versus dupixent. And so long-term prospect and catalyst for growth are very good for having both mechanisms. And we also see a catalyst for growth in alopecia areata to be first in disease with aluminum. And so we feel very good about our chances to not only compete, but also to have significant growth and have meaningful outcomes for patients.
spk10: Thanks, Ilya. Seamus, thanks for your questions. Next caller, please.
spk12: Thank you. Our next question comes from the line of Louise Chen with Kantor. Please go ahead.
spk17: Hi. Thanks for taking my questions here. So the first question I had for you was on leberkizumab. What do you think will differentiate your products from others that are already approved and those in development? And do you plan to pursue that for any other indications? And then second question is on LOXO 305 plus LOXO 338. What do you think your competitive advantages are here versus others that are trying to do the same thing? Thank you.
spk10: Great. Thanks, Louise. We'll go to Ilya for the first question and Jake for the second.
spk11: Yeah, Louise, thank you for the question about Leberkizumab. In terms of area differentiation, the focus for Leberkizumab is not only to look at the efficacy on SKIM, but also one of the more impactful symptoms related to atopic dermatitis is itch, and so we believe we may have the opportunity to differentiate an itch, which also has impact on sleep, and we believe that Leberkizumab may have a better safety profile. And so that's where we believe we can differentiate. And so we're excited to get the results for leprechaun at the back half of the year. In terms of new indications, I think it's early to take a look at any new indications. We're obviously evaluating opportunities to grow leprechaun, but our full focus right now is making sure we have success in atopic dermatitis.
spk09: Just to jump in on top of that, of course, there will be a dosing convenience and dosing certainty benefit with Lebri as well. Thanks, Jim.
spk08: Thanks for the question, Louise, about pertobrutinib LOXO305 and LOXO338, the BCL2 inhibitor. I think as it relates to differentiation, I'd point out a few things here. First off, obviously, as I think you and others know, pertobrutinib itself is a differentiated BTK inhibitor that we believe affords certain advantages in combination. Obviously, we need to prove that clinically, but that's our hypothesis right now. So that sort of stands on its own. The LOXO338 program, the BCL2 inhibitor, we're putting into the clinic this year, and obviously important that that drug meets its human pharmacology goals. so that we know that it itself is on track as a drug. Should that prove to be the case, which we expect it to, we will then look to combine these two agents. I think when you look out at others that are combining BTK and BCL2, the latter largely being venetoclax, I think what you see is a very fragmented landscape of asset ownership across companies. And as a result of that, some oftentimes perverse incentives about how to combine those drugs and where. We think it's important that if you have a new and differentiated BTK inhibitor like we believe we do with pertobrutinib, we thought it was strategically important to own our own BCL2 inhibitor. And so, we think we'll be really the only player in the field who owns both agents outright. So, that to us is a key differentiating feature downstream. But it's still a bunch of hoops we have to jump through to enable that combination.
spk10: Thanks, Jake. Luis, thanks for your questions. Next caller, please.
spk12: Thank you. Next we go to the line of Carter Gould with Barclays. Please go ahead.
spk07: All right. Good morning. Thanks for the comprehensive updates and for taking the question. I guess first for Dan or Mike, you guys posted details. of the summit study of Terzepratide and HFPAF recently. And I think the design, size, and timeline were all surprising relative to expectations. So, you know, I guess getting to a readout much faster than some had expected. Can you maybe just walk through some of those key design choices and the extent regulators have bought in and also confirm that that single study would be sufficient for approval in that setting? And then also, you know, historically Lilly has done a, I think, done a better job of sort of franchise building in certain areas and some of its peers. Now, with sort of Miracuzumab de-risking data, can you talk around how you're thinking about building around that GI portfolio? Thank you.
spk10: Thanks, Carter. We'll go to Mike for the question on Terzepatide, and Ilya for the question on MIRI.
spk14: Yeah, thanks for the question on the SUMMIT trial. We're bullish on the opportunity for Terzepatide in HFPAF. When you look at that, it's a really a large unmet need with nearly 4 million people living with HEPPF, heart failure, leading cause of hospitalization in the U.S. When you look at scientifically, you do see that there is a BC-related HEPPF phenotype that we believe that triseptide can play a large role in helping out. And so that's what really drove our investment in Summit, and I think the team has done a nice job of coming up with a creative approach that will provide, I think, robust data for payers and clinicians to make that decision. So, I think we're very confident in both our clinical trial design as well as the commercial opportunity.
spk10: Thanks, Mike. We'll go to Ilya for the next answer.
spk11: Sure. Yeah, Carter, listen, as you noted, in terms of building franchises across immunology, we've built up our scale in dermatology and excited about increasing number of treatments there. The same with rheumatology and the hope for finding lupus as well. And then in GI, mirakizumab will be our first entrant into GI with ulcerative colitis and Crohn's disease. And then we do have a pretty robust pipeline in both Phase I and proof-of-concept studies, in particular IL-2 conjugate, that we're studying for ulcerative colitis as well. And we look forward to bringing out new treatments across all three of those areas in the coming years.
spk10: Thanks, Ilya. Carter, thanks for your questions. Next caller, please.
spk12: Thank you. Our next question comes from Tim Anderson with Wolf Research. Please go ahead.
spk06: Thank you. A couple of questions. On Verzinio and the CDK class more broadly, can you talk about what you're seeing in the U.S. in terms of rebating for this oral oncology category? My understanding is that the level of rebates may be stepping up, and I'm not sure which company or companies are driving that. Maybe it's Pfizer driving that as they try to hang on to market share. But what's the outlook for gross to net price trends in this category? And then on Tyvid, your P1 from InnoVent, a Chinese company, you note that you'll file for approval on non-small cell lung in the U.S. this year. It's really hard for me to see how you gain any share with this product given what would be a limited label and given payer and prescriber dynamics where in things like Part B, you can't really compete on price. So what's realistic to expect with this product from a commercial perspective, not only U.S., but in other Western markets like Europe?
spk10: Thanks, Tim. We'll go to Ann White for both of those.
spk20: Well, thanks, Tim, for the question on Versenio. So I think, as you're mentioning, it's an incredibly competitive market with the CDK4-6s, and so we and others continue to do what we need to do to make sure that patients get access to the right medicines. So... So we have, obviously, a strong strategy there. I can't comment on the specifics, but we do see competition. And really what we're seeing, I think you're seeing in Verzenio, what we're seeing is an incredibly nice trend growing in Q1. As you saw, we had positive momentum with the U.S. strong share growth in March, and we saw TRX of over 17 percent and NBRX of over 28 percent. So, and this is despite, as you've noticed, a modest year-on-year TRX market decline. So I think what we're seeing is both from a payer strategy, but also very much from a data strategy, we're seeing that Versenio is growing its share nicely. And so I like how all of our different programs are coming together. And obviously the data in adjuvant breast cancer reinforced growing awareness that these medicines are different. But what really has been the focus for our execution has been capitalizing on the positive OS data and making sure that people are aware of that. And we're seeing more trial more adoption as we go through that. So very pleased how all of our strategies with Versenio are coming together. On Tybit, yes, I mean, as you've mentioned, it's a competitive space, obviously. And while I can't really comment on our commercial strategy prior to approval, you can be reassured that we're looking at ways to differentiate and really add value to this innovative class of medicines. So obviously, we know that there's certain commercial approaches we'll have to take to capture share as really a late entrant in the field. But we see opportunity here, and obviously this deal made sense with the partnership that we've had with InnoVent, and we're committed to the U.S. submission this year. And so more to come as we look to launch the product and share that strategy and how we intend to make an opportunity here. But as you said, I wouldn't assess this as a large opportunity for Lilly, but an opportunistic one that we think makes sense, makes sense for patients globally and driving value for them.
spk10: Thanks, Dan. Tim, thanks for your questions. We'll move to the lightning round so we can try to get everyone in. Our answers will be brief, and we'll actually ask each of you to only have one question for us. The next caller, please.
spk12: Thank you. Next, we have Andrew Baum with Citi. Please go ahead.
spk02: Yeah, a question for Dan. On the Zemio and the Monarch e-filing, as you outlined, the survival data is thankfully going to take a long time to mature. Is the answer that the FDA is looking for more about further maturation of progression-free survival or, sorry, disease-free survival, just given the historic precedence of the Penelope B data with palbocyclic, where you had separation but then coming together? Isn't that really what the FDA wants, given if you're waiting for survival, you could be waiting for a very long time indeed?
spk05: Thanks, Andrew. Dan? I'll just take it quickly. No, Andrew, the focus here is on the overall survival. On the distant relapse-free survival, as we commented, the curves are not coming together. They're actually separating more. It's improving as we get more events. I'm not aware of any concerns around that.
spk10: Got it. Thank you. Thanks, Dan. Thanks, Andrew, for your question. Next caller, please.
spk12: Thank you, ladies. Next, we go to the line of Steve Scala with Cowan. Please go ahead.
spk04: Thank you. I think it was stated that the number of CV events in past four has been reached, if I heard that correctly. If that's correct, then it looks like the study is going to achieve its endpoint earlier than expected. So my question is, is that either confidence building or concerning? Are you worried COVID-19 cardiovascular effects may have impacted the accrual of events? And if there's hepatitis, transworts, and insulin glatergine, can you still file? Thank you.
spk10: Thanks, Steve. We'll go to Mike on that.
spk14: Yeah, thanks for the question. No, we have no concerns. We have reached the number we needed to complete the trial. We're getting patients back in. We'll have that data. Should start to see top line in May, and we'll release that information before the end of the quarter. We're very, very excited about Tricepatide and very confident in its CV profile. I'm looking forward to seeing this for the past four days.
spk10: Thanks, Mike, Steve. Thanks for your question. Next caller, please.
spk12: Thank you. Next, we go to the line of Terrance Flynn with Goldman Sachs. Please go ahead.
spk23: Hi. Thanks for taking the questions. I was just wondering, on Monarchy, if there's any possibility of an NCCN listing before the FDA action? Can you give us an update on the Retevmo launch dynamics this quarter? Thank you.
spk10: Thanks, Terrence. We'll go to Ann for the question on Versenio and Retevmo.
spk20: Thanks for the question. So, on Monarchy and NCCN, I really can't comment for them. So, obviously, we feel that this data is incredibly impactful. I think one of our thought leaders called it the most notable development in HER2-positive breast cancer in the last two decades. But we'll just have to wait and see what NCCN decides to do. And then on Rotemo, the launch is going well. So we had a virtual launch in May. We finished 2020 with 37 million in sales. And we see cause of momentum in Q1. So we've had a great engagement with customers. Unneeded brand awareness is strong. So we're quite pleased. And this is an incredibly important medicine, as you know. Some patients over an 80% response rate. So great response from the customers. Very enthusiastic about what we're seeing so far.
spk10: Thanks, Anne. Karen, thanks for your questions. Next caller, please.
spk12: Thank you. Our next question comes from Ronnie Gall with Bernstein. Please go ahead.
spk21: Good morning, and thank you for making the time. So we are seeing you adopting cost-conscious strategies on both TAL and on Mirakizumab. And I was kind of wondering, if you're going to look forward five years, where do you see immunology pricing then goes in terms of dollars per year? It's right now in the low to mid-30s, the way we can see it. Five years from now, are we going to be in the mid-20s, under-20s? What do you see that the band price is looking like?
spk10: Thanks, Ronnie. We'll go to Ilya for questions on immunology pricing trends.
spk11: Yeah, Ronnie, thanks for the question on immunology. In terms of our focus, it's more related to looking at opportunities for growth. We have a long runway for TALTS, and so we do believe that TALTS is kind of at the foundation of our immunology strategy. We have numerous head-to-head studies and real-world evidence to suggest that TALTS is a best-in-disease treatment. And as part of our growth strategy, looking at mirakizumab and GI, we do believe that within the next 5 to 10 years, we can, across multiple mechanisms in those three specialized groups, dermatology, rheumatology, and GI, have significant growth and become a top-tier immunology company. In terms of pricing, I think they're all very competitive fields, and so our goal is to have great evidence and create access opportunities for patients that need these treatments.
spk10: Thanks, Ilya. Ronnie, thanks for your question. Next caller, please.
spk12: Thank you. Next, we go to the line of Carrie Holford with Ehrenberg. Please go ahead.
spk01: Thank you. Just on the COVID antibodies, I wonder if you can just discuss the disconnect between your lower 2021 self-guidance here and the higher associated spend. And with that context, do you have a budget cap in mind for your ongoing COVID investments? Thank you.
spk10: Thanks, Carrie. We've got enough for that.
spk18: Sure. Thanks, Carrie. Let me start with the budget. So we did increase our guidance for the COVID antibody investment from 300 to 400 to 400 to 500. And the investment that we've announced this morning is really to address the growth in variants that we see globally and looking at additional antibodies that could address that. The lowering on the high end of the range really relates to the changes you've seen here in the U.S. government as well as what we see in terms of progression of the disease. And this is one I know that is more challenging to forecast, given that there's not a lot of TRX data or data for you to look at, and we'll continue to update, obviously, with every quarter.
spk09: And maybe just to add as a mindset thing, we didn't get into this because we were thinking about margins or business profile. It was to be useful during the pandemic, which is still going on, obviously, raging in other parts of the world. One other driver for the top line is that increasingly we'll be selling our products into lower-priced markets or giving it away because that's where the disease is. And when the pandemic period ends, I think we can then take a different look at this enduring business, but we're not there yet. So we're making the investments we need to to be useful and selling the product where it's needed at the price structure we had previously announced, which is heavily discounted in low GDP markets.
spk10: Thanks, David, and Carrie, thanks for your question. Next caller, please.
spk12: Thank you. Next, we go to the line of Umar Rafat with Evercore. Please go ahead.
spk19: Hi, thanks for taking my question. Dan, last we spoke in mid-March, it seems like you hadn't had a lot of regulatory discussions on Denanimab, but it does feel like you've had them now. So I'm curious, FDA feedback on the new endpoint, IADRS, as well as the Bayesian analysis. And also, very briefly, on CD73, There's an interesting emerging signal in some of the other CD73s in pancreatic setting. I noticed you guys discontinued. Would love to find out any additional color.
spk05: Thanks, Seymour. Dan? Yeah, sure. So, FDA feedback has been continuing, I should say. We had some, and it continues to come. I think, you know, our view here is unchanged. We previously said that The FDA has concerns around address because it combines cognition and function, and there's always a risk that you could have a positive signal on address driven by cognition with no benefit on function or function going the other way or vice versa, and that wouldn't be acceptable for approval of a new drug. So that's the risk there. On the C73 Phase I termination, I don't have additional comments.
spk10: Thanks, Dan. Umar, thanks for your question. Next caller, please.
spk12: And last question comes from Gilbert with Truist Security. Please go ahead.
spk03: Thanks. Dan on tenuzumab, is the outlook any more hopeful than the optics of the adcom vote? And can you comment on where pain fits into your overall R&D priority list at this point? Thanks.
spk05: Sure. Greg, thanks for the question. Pain is still a really important unmet medical need. Clearly, the regulatory bar is high here in terms of safety, and we saw that from the Tenezumab Advisory Committee meeting, which was a pretty decisive outcome there and one that we were disappointed in.
spk10: Thanks, Dan. Greg, thanks for your question. Back to Dave for the close.
spk09: Okay. Thanks, Kevin. We appreciate your participation in today's call and your interest in Eli Lilly and Company. 2021 has begun with good momentum in our underlying business. We remain focused on executing our innovation-based strategy to bring new medicines to patients and create value for all our stakeholders. As we continue to scale our diverse commercial portfolio, complemented by a pipeline of industry-leading opportunities, we believe Lilly continues to be a compelling investment. Thanks again for dialing in today. Please follow up with our IR team if you have any questions we have not addressed on today's call. Hope everyone has a great day.
spk12: Thank you, ladies and gentlemen. That does conclude our conference for today. We thank you for your participation and for using AT&T Event Conferencing Service. You may now
Disclaimer